Related Experiment Video
Updated: Jun 23, 2026
Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
Published on: January 3, 2013
Yuanhuacine Is a Potent and Selective Inhibitor of the Basal-Like 2 Subtype of Triple Negative Breast Cancer with
Charles S Fermaintt1, Thilini Peramuna2, Shengxin Cai2
1Department of Pharmacology, Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA.
Abstract:
The heterogeneity of triple negative breast cancer (TNBC) has led to efforts to further subtype this disease with the hope of identifying new molecular liabilities and drug targets. Furthermore, the finding that TNBC is the most inherently immunogenic type of breast cancer provides the potential for effective treatment with immune checkpoint inhibitors and immune adjuvants. Thus, we devised a dual screen to identify compounds from natural product extracts with TNBC subtype selectivity that also promote the expression of cytokines associated with antitumor immunity. These efforts led to the identification of yuanhuacine (1) as a potent and highly selective inhibitor of the basal-like 2 (BL2) subtype of TNBC that also promoted an antitumor associated cytokine signature in immune cells. The mechanism of action of yuanhuacine for both phenotypes depends on activation of protein kinase C (PKC), defining a novel target for the treatment of this clinical TNBC subtype. Yuanhuacine showed potent antitumor efficacy in animals bearing BL2 tumors further demonstrating that PKC could function as a potential pharmacological target for the treatment of the BL2 subtype of TNBC.
Insights
Researchers identified yuanhuacine as a selective inhibitor for basal-like 2 triple-negative breast cancer (TNBC). This compound activates protein kinase C (PKC), showing potential for targeted TNBC therapies and immune response.
Area of Science:
- Oncology
- Immunology
- Natural Products Chemistry
Background:
- Triple-negative breast cancer (TNBC) is highly heterogeneous, necessitating further subtyping for novel therapeutic targets.
- TNBC's immunogenic nature suggests potential efficacy with immune-based therapies like checkpoint inhibitors.
- Identifying subtype-selective compounds that modulate anti-tumor immunity is crucial for advancing TNBC treatment.
Purpose of the Study:
- To screen natural product extracts for compounds selectively targeting TNBC subtypes.
- To identify agents that enhance anti-tumor immune responses by promoting cytokine expression.
- To discover novel molecular liabilities and therapeutic targets within TNBC subtypes.
Main Methods:
- A dual screening approach was employed to identify compounds with TNBC subtype selectivity and immune-modulating properties.
- Natural product extracts were evaluated for their ability to inhibit specific TNBC subtypes and induce antitumor cytokine profiles.
- Mechanism of action studies focused on the role of protein kinase C (PKC) in mediating yuanhuacine's effects.
Main Results:
- Yuanhuacine was identified as a potent and selective inhibitor of the basal-like 2 (BL2) TNBC subtype.
- Yuanhuacine demonstrated the ability to promote an antitumor-associated cytokine signature in immune cells.
- The compound's mechanism involves the activation of protein kinase C (PKC) for both its cytotoxic and immunomodulatory effects.
- Yuanhuacine exhibited significant antitumor efficacy in preclinical models of BL2 TNBC.
Conclusions:
- Yuanhuacine represents a promising therapeutic candidate for the basal-like 2 subtype of triple-negative breast cancer.
- Protein kinase C (PKC) activation by yuanhuacine defines a novel therapeutic target for BL2 TNBC.
- The dual action of yuanhuacine on cancer cells and the immune system highlights its potential in targeted cancer immunotherapy.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
